We have previously shown that a subcutaneous injection of glucagon-like peptide-2 (GLP-2)
at 9 am in fasting postmenopausal women results in a dose-dependent decrease in the�…

We have previously shown that a single subcutaneous injection of glucagon-like peptide-2
(GLP-2) at 10 pm in postmenopausal women results in a dose-dependent decrease in the�…

We have previously shown that repeated dosing of glucagon-like peptide-2 (GLP-2) at 10
pm in postmenopausal women for 14 days results in a dose-dependent decrease in the�…

Background Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-
2 (GLP-2) are gut hormones secreted in response to food ingestion, and they have been�…

Collagen type I fragments, reflecting bone resorption, and release of gut hormones were
investigated after a meal. Investigations led to a dose escalation study with glucagon like�…

OBJECTIVE: In healthy subjects, subcutaneous injections of GLP-2 have been shown to
elicit dose-related decrease in the bone resorption marker, carboxy-terminal telopeptide of�…

Bones have been suggested to be a target for glucagon like peptide 1 (GLP 1); however,
studies of the effects on human bones so far have given diverging results. We hypothesized�…

Abstract Background Glucagon-like peptide-2 (GLP-2) and glucose-dependent
insulinotropic polypeptide (GIP) both inhibit bone resorption in humans but the underlying�…

The diurnal variation in bone resorption markers is poorly understood and may contain
essential information about regulation of bone resorption. To explore the acute regulation of�…

Bone resorption shows a circadian rhythm in human subjects, but the physiological
mechanisms underlying this rhythm are unknown. We compared the circadian rhythm of�…